Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98


The anticancer potential of metformin on prostate cancer.

Zaidi S, Gandhi J, Joshi G, Smith NL, Khan SA.

Prostate Cancer Prostatic Dis. 2019 Jan 16. doi: 10.1038/s41391-018-0085-2. [Epub ahead of print]


A review for clinicians: Prostate cancer and the antineoplastic properties of metformin.

Hankinson SJ, Fam M, Patel NN.

Urol Oncol. 2017 Jan;35(1):21-29. doi: 10.1016/j.urolonc.2016.10.009. Epub 2016 Nov 9. Review.


Metformin: A Bridge between Diabetes and Prostate Cancer.

Zingales V, Distefano A, Raffaele M, Zanghi A, Barbagallo I, Vanella L.

Front Oncol. 2017 Oct 11;7:243. doi: 10.3389/fonc.2017.00243. eCollection 2017. Review.


Growth Modulation of Diabetic Factors and Antidiabetic Drugs on Prostate Cancer Cell Lines.

Chien SW, Kuo DY, Liao JM, Wang PS, Yu CH.

Chin J Physiol. 2016 Apr 30;59(2):109-18. doi: 10.4077/CJP.2016.BAE368.


Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer.

Crawley D, Chandra A, Loda M, Gillett C, Cathcart P, Challacombe B, Cook G, Cahill D, Santa Olalla A, Cahill F, George G, Rudman S, Van Hemelrijck M.

BMC Cancer. 2017 Jul 21;17(1):494. doi: 10.1186/s12885-017-3458-3.


Metformin effects on biochemical recurrence and metabolic signaling in the prostate.

Winters B, Plymate S, Zeliadt SB, Holt S, Zhang X, Hu E, Lin DW, Morrissey C, Wooldridge B, Gore JL, Porter MP, Wright JL.

Prostate. 2015 Nov;75(15):1694-703. doi: 10.1002/pros.23049. Epub 2015 Jul 22.


Combination Therapies Using Metformin and/or Valproic Acid in Prostate Cancer: Possible Mechanistic Interactions.

Tran LNK, Kichenadasse G, Sykes PJ.

Curr Cancer Drug Targets. 2018 Jul 23. doi: 10.2174/1568009618666180724111604. [Epub ahead of print]


Metformin Elicits Antitumor Effects and Downregulates the Histone Methyltransferase Multiple Myeloma SET Domain (MMSET) in Prostate Cancer Cells.

White-Al Habeeb NM, Garcia J, Fleshner N, Bapat B.

Prostate. 2016 Dec;76(16):1507-1518. doi: 10.1002/pros.23235. Epub 2016 Jul 12.


Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells.

Berstein LM, Yue W, Wang JP, Santen RJ.

Breast Cancer Res Treat. 2011 Jul;128(1):109-17. doi: 10.1007/s10549-010-1072-z. Epub 2010 Aug 4.


Metformin: taking away the candy for cancer?

Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO, de Vries EG.

Eur J Cancer. 2010 Sep;46(13):2369-80. doi: 10.1016/j.ejca.2010.06.012. Epub 2010 Jul 23. Review.


Metformin Has Positive Therapeutic Effects in Colon Cancer and Lung Cancer.

Henderson D, Frieson D, Zuber J, Solomon SS.

Am J Med Sci. 2017 Sep;354(3):246-251. doi: 10.1016/j.amjms.2017.05.006. Epub 2017 May 19.


Impact of Metabolic Diseases, Drugs, and Dietary Factors on Prostate Cancer Risk, Recurrence, and Survival: A Systematic Review by the European Association of Urology Section of Oncological Urology.

Campi R, Brookman-May SD, Subiela Henríquez JD, Akdoğan B, Brausi M, Klatte T, Langenhuijsen JF, Linares-Espinos E, Marszalek M, Roupret M, Stief CG, Volpe A, Minervini A, Rodriguez-Faba O.

Eur Urol Focus. 2018 Apr 13. pii: S2405-4569(18)30090-7. doi: 10.1016/j.euf.2018.04.001. [Epub ahead of print] Review.


High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.

Marques RB, Aghai A, de Ridder CMA, Stuurman D, Hoeben S, Boer A, Ellston RP, Barry ST, Davies BR, Trapman J, van Weerden WM.

Eur Urol. 2015 Jun;67(6):1177-1185. doi: 10.1016/j.eururo.2014.08.053. Epub 2014 Sep 12.


Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners.

Sarfstein R, Friedman Y, Attias-Geva Z, Fishman A, Bruchim I, Werner H.

PLoS One. 2013 Apr 19;8(4):e61537. doi: 10.1371/journal.pone.0061537. Print 2013.


Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.

Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB.

Eur Urol. 2015 Mar;67(3):470-9. doi: 10.1016/j.eururo.2014.09.049. Epub 2014 Oct 8. Review.


The pentacyclic triterpenoid, plectranthoic acid, a novel activator of AMPK induces apoptotic death in prostate cancer cells.

Akhtar N, Syed DN, Khan MI, Adhami VM, Mirza B, Mukhtar H.

Oncotarget. 2016 Jan 26;7(4):3819-31. doi: 10.18632/oncotarget.6625.


Anti-cancer Effects of Metformin: Recent Evidences for its Role in Prevention and Treatment of Cancer.

Kheirandish M, Mahboobi H, Yazdanparast M, Kamal W, Kamal MA.

Curr Drug Metab. 2018;19(9):793-797. doi: 10.2174/1389200219666180416161846.


Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer.

Rozengurt E, Sinnett-Smith J, Kisfalvi K.

Clin Cancer Res. 2010 May 1;16(9):2505-11. doi: 10.1158/1078-0432.CCR-09-2229. Epub 2010 Apr 13.


Metformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling.

Malaguarnera R, Sacco A, Morcavallo A, Squatrito S, Migliaccio A, Morrione A, Maggiolini M, Belfiore A.

Endocrinology. 2014 Apr;155(4):1207-21. doi: 10.1210/en.2013-1925. Epub 2014 Jan 17.


Metformin targets c-MYC oncogene to prevent prostate cancer.

Akinyeke T, Matsumura S, Wang X, Wu Y, Schalfer ED, Saxena A, Yan W, Logan SK, Li X.

Carcinogenesis. 2013 Dec;34(12):2823-32. doi: 10.1093/carcin/bgt307. Epub 2013 Oct 15.

Supplemental Content

Support Center